tbuckley/cabot-search huggingface dataset:
SPYGLASSDS GUIDED LITHOTRIPSY FOR PANCREATIC DUCT STONES IN SYMPTOMATIC, TREATMENT REFRACTORY CHRONIC PANCREATITIS – 12 MONTHS FOLLOW UP ON CLINICAL, TECHNICAL SUCCESS AND QUALITY OF LIFE
Authors: C Gerges, D Pullmann, M Schneider, PD Siersema, H Neuhaus, EJM van Geenen, T Beyna
Journal: Endoscopy (2019)

Pancreatic duct (PD) stones are a common complication in chronic calcifying pancreatitis (CCP) and can contribute to pain onset and exacerbation. Digital-single-operator-pancreaticoscopy (d-SOP) guided lithotripsy was shown to be a promising option of therapy regarding technical success (95% ductal clearance) and clinical success after3 – 6 months FU (achieved in 95%) 1. There is only little evidence of mid-and long-term technical and clinical success or impact on quality of life2.
INTEREST OF UPPER GASTROINTESTINAL ENDOSCOPY BEFORE BARIATRIC SURGERY
Authors: S Mrabet, K Dhouioui, F Hamila, I Akkari, E Ben Jazia, R Letaief
Journal: Endoscopy (2019)

The search for Helicobacter Pylori (HP) infection is recommended systematically before bariatric surgery. The aim of our study is to determine the endoscopic and histological aspects of gastric lesions in patients with morbid obesity.
Increasing Suicide Rates in Early Adolescent Girls in the United States and the Equalization of Sex Disparity in Suicide
Authors: Joan Luby, Sarah Kertz
Journal: JAMA Network Open (2019)

Donna A. Ruch, PhD; Arielle H. Sheftall, PhD; Paige Schlagbaum, BS; Joseph Rausch, PhD; John V. Campo, MD; Jeffrey A. Bridge, PhD
La prévalence des adénomes avancés selon la taille des polypes colorectaux
Authors: F Aissaoui, M Zakhama, I Jemni, S Ben Amor, A Guediche, W Bouhlel, W Ben Mansour, HL Mohamed, BC Nabil, L Safer
Journal: Endoscopy (2019)

La résection des polypes diagnostiqués à la coloscopie permet d'éviter l'évolution des adénomes vers un cancer colorectal. La séquence de transformation est d'autant plus courte que l'adénome est avancé.
MORE LESIONS PER PATIENT DETECTED WITH HIGH-QUALITY VERSUS ADEQUATE COLON CLEANSING: A POST HOC ANALYSIS OF UNIFORM SEGMENTAL CLEANSING SCORES USING THE HAREFIELD CLEANSING SCALE
Authors: R Jover, J Manning, S Mokashi, C Hassan
Journal: Endoscopy (2019)

Effective colonoscopy requires colon cleansing success which is usually based on the least clean colon segment; one poorly cleansed segment triggers an overall failure. This complicates the analysis of cleansing quality versus lesion detection. We therefore analysed the relative lesion detection in patients who had the same cleansing score in all colon segments.
SOLITARY NEEDLE TRACT SEEDING METASTASES FOLLOWING PANCREATIC CANCER RESECTIONS WITH PREVIOUS EUS-FNA
Authors: M Lovecek, P Skalicky, O Urban, B Mohelnikova-Duchonova, P Falt, V Zoundjiekpon, J Tesarikova, H Svebisova, R Lemstrova, J Ehrmann, C Neoral
Journal: Endoscopy (2019)

Pancreatic cancer (PDAC) seeding metastases following EUS-FNA is not frequent. However, the accurate frequency of this dissemination of PDAC is not known. A progression of the disease recurrence leading to death during the first two years following radical surgery is faster than the growth of seeding metastasis into its detectable size. In a case, that an isolated seeding metastasis develops, it becomes a serious complication involving patient's prognosis. Reports regarding this kind of dissemination have been increasing during last few years. We present two cases of seeding metastases. One has been following left pancreatectomy. Second is an unique case of metastasis following pylorus preserving hemipancreatoduodenectomy, as there is not previously published such a case.
Mammalian Target of Rapamycin Inhibitors, New Drugs for Beta‐Catenin–Mutated Hepatocellular Carcinomas?
Authors: Christine Perret, Thomas Decaens
Journal: Hepatology (2019)

Perret, Christine Ph.D.1,2,3; Decaens, Thomas M.D., Ph.D.4,5,6Editor(s): Corey, Kathleen E.7; Malhi, Harmeet8 Author Information
Comment informer les professionnels de santé sur les Dispositifs Médicaux? Création en endoscopie digestive d'un outil pilote informatique connecté au livret des Dispositifs Médicaux de l'hôpital
Authors: C Danet, V Duhalde, A Culetto, K Barange, L Buscail, C Barrué, I Labadens, P Cestac
Journal: Endoscopy (2019)

La communication au sens large et celle d'informations sur le bon usage des Dispositifs Médicaux (DM) dans un Centre Hospitalier est primordiale mais est souvent non optimale, et ces informations n'atteignent pas souvent les professionnels de santé pour être prises en compte dans leur pratique quotidienne.
Breast cancer early recurrences in young women
Authors: S. Cima, E.K. Cekani, M. Valli, A. Richetti
Journal: Annals of Oncology (2019)

Background: Breast cancer is the most common cause of cancer in women worldwide, with more aggressive clinical behavior and poor outcomes in younger patients. This is to their increased risk of presenting with biologically aggressive types of cancer and at more advanced stage. Many studies have attempted to identify risk factors for local recurrence and distant metastases. The aim of this retrospective study was to analyze rates of recurrence in young patients with breast cancer treated at Ticino Breast Unit. Methods: We analyzed medical records of 381 women ≤50 years old, with stage I-III invasive breast cancer, treated with curative intent, from 2010 to 2017. Demographics, tumor biology, type of surgery, neoadjuvant and adjuvant therapy, site of recurrence, time of recurrence and survival were assessed. Overall survival (OS) was defined as the time period from diagnosis to death from any cause. Disease-free survival (DFS) was defined as the time period from surgery to the first loco regional recurrence and/or metastases. Survival curves were calculated using Kaplan-Meier method. Results: The median age at the time of diagnosis was 45 years (range 23 to 50 years). The median follow-up was 45.6 months (range 1 to 105 months). Twenty-two patients (5.8%) were lost to follow-up. Tumor relapse occurred in 29 cases (7.6%), among which 9 patients died. Fourteen patients (3.7%) developed a loco-regional recurrence, 6 patients (1.6%) developed distant metastases and 9 patients (2.4%) loco-regional plus distant metastases. The most common site of loco-regional failure was the omolateral breast (11 patients). Two patients developed a second tumor in the contralateral breast. The median interval to recurrence was 31 months (range 3 to 87 months). The 3-year and 5-year risk for loco-regional recurrence was 4.7% and 9.5% respectively. The 3-years and 5-year DFS was 94.3% and 91.2% respectively. The 5-years OS was 93.3%. Conclusions: Loco-regional recurrence and distant metastases rates of our population do not differ from those published in literature. Further analysis is needed to recognize biological and clinical risk factors for recurrence, with the aim of identifying prognostic models and addressing therapies. Legal entity responsible for the study: Radiation Oncology Clinic. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
CHARACTERIZATION OF ESOPHAGEAL MICROBIOTA IN PATIENTS WITH BARRETT'S ESOPHAGUS AND ESOPHAGEAL ADENOCARCINOMA
Authors: LR Lopetuso, G Ianiro, S Pecere, M Severgnini, G Quaranta, I Boskoski, T Camboni, F Scaldaferri, M Riccioni, L Masucci, C Consolandi, A Gasbarrini, G Costamagna, G Cammarota
Journal: Endoscopy (2019)

The aim of our study was to characterize esophageal microbiota composition in patients with BE and EAC.
Influence on quality of life of chemotherapy scheduling for patients with advanced HER2-negative breast cancer
Authors: A.K.M. Claessens, R. Timman, J.J. Busschbach, J.M. Bouma, J.M. Rademaker-Lakhai, F.L.G. Erdkamp, V.C.G. Tjan-Heijnen, M.M.E.M. Bos
Journal: Annals of Oncology (2019)

Background: The phase III Stop&Go study randomized patients with advanced breast cancer to two times four intermittent cycles or to eight continuous cycles of first- and second-line chemotherapy, yielding inferior overall survival (OS) with intermittent scheduling. Here we report on the prospectively planned quality of life (QoL) analyses. Methods: QoL was measured by RAND-36 questionnaires every 12 weeks during study treatment and follow-up. Physical and mental component scores were calculated and presented as T-scores with a mean of 50 and a standard deviation (SD) of 10 for the normal population, with higher scores representing better QoL. All patients who responded to baseline questionnaires with sufficient valid data were included. The primary objective was to describe the course of physical and mental QoL for both treatment arms, and to estimate differences in changes from baseline in physical and mental QoL between arms. These differences were estimated longitudinally with multilevel linear regression analyses with a follow up period of 30 months. An effect size of 0.5 SD (5 points) was considered clinically meaningful. Results: A total of 398 patients were included with a median follow-up of 11.3 months (IQR 5.6 - 22.2). Mean baseline scores were 37.9 and 38.3 for physical, and 44.7 and 42.5 for mental QoL for intermittent and continuous treatment respectively. Physical QoL declined linearly in the intermittent arm causing a clinically meaningful difference of 5.68 points at 24 months (p < 0.001), while scores in the continuous arm stabilized after a decline of ± 3.5 points at 12 months. Conversely, mental QoL was fairly stable and even improved by 1.86 (p = 0.012) and 2.53 points (p = 0.001) at 12 months for intermittent and continuous treatment. When comparing the arms for both components in changes from baseline, the maximum differences were 3.11 points (p = 0.069) for physical and 3.32 points (p = 0.057) for mental scores, both measured at 30 months and in favor of continuous treatment. Conclusions: Intermittent chemotherapy was less effective and showed a trend for worse impact on QoL compared to continuous chemotherapy in advanced breast cancer. Clinical trial identification: EudraCT 2010-021519-18; BOOG 2010-02. Legal entity responsible for the study: Dutch Breast Cancer Research Group (BOOG). Funding: F. Hoffmann-La Roche Ltd, The Netherlands TEVA Nederland, B.V. Disclosure: F.L.G. Erdkamp: Honoraria, consulting/advisory role: Roche, Novartis. V.C.G. Tjan-Heijnen: Honoraria: E. Lilly, Pfizer; Funding for her institution: E. Lilly, Roche, Eisai, Pfizer, Novartis; Travel expenses: E. Lilly, Pfizer, Novartis, Roche; Consulting or advisory role: E. Lilly, Pfizer, Roche. All other authors have declared no conflicts of interest.
EXPLANT OF INTRAGASTRIC BALLOON WITH SEVERE FUNGAL COLONIZATION: HOW DO I DO IT?
Authors: M Silva, M Dos Passos Galvão Neto, E Grecco, AL Santos, S Gomes, G Macedo, LG de Quadros
Journal: Endoscopy (2019)

Placement of a intragastric balloon (IGB) by endoscopic route is an efficient, safe and minimal invasive procedure for the treatment of obesity. Fungal colonization of IGBs is a rare adverse event that can lead to serious complications during IGB removal. The technique described herein may facilitate extraction in these cases and reduce the risk of complications, as this is a safe option for balloon removal after intense fungal colonization.
Re: Philip S. Macklin, Mark E. Sullivan, Charles R. Tapping, et al. Tumour Seeding in the Tract of Percutaneous Renal Tumour Biopsy: A Report on Seven Cases from a UK Tertiary Referral Centre. Eur Urol 2019;75:861–7
Authors: Maxine G B Tran, Ravi Barod, Axel Bex
Journal: European Urology (2019)
ELECTROCAUTERY SETTING DOES NOT AFFECT EFFICACY AND SAFETY OF ENDOSCOPIC RESECTION OF LARGE COLORECTAL POLYPS
Authors: H Pohl, IS Grimm, MT Moyer, MK Hasan, D Pleskow, BJ Elmunzer, MA Khashab, O Sanaei, FH Al-Kawas, SR Gordon, A Mathew, JM Levenick, HR Aslanian, F Antaki, D Renteln, SD Crockett, A Rastogi, JA Gill, RJ Law, PA Elias, M Pellise, TA Mackenzie, DK Rex
Journal: Endoscopy (2019)

The type of electrocautery setting that should be used for polyp resection has long been a matter of debate. It remains unknown whether the type of electrocautery setting affects resection efficacy, risk of adverse events, or recurrence rates. We aimed to compare two commonly used electrocautery settings for endoscopic mucosal resection of large colorectal polyps in a multicenter, randomized trial.
COLD ENDOSCOPIC MUCOSAL RESECTION OF 8 – 20MM SESSILE SERRATED POLYPS: A PROSPECTIVE TRIAL
Authors: V Papastergiou, M Fragkaki, M Velegraki, A Mpitouli, E Vardas, E Voudoukis, N Mathou, A Giannakopoulos, L Giannikaki, D Apessou, K Paraskeva, G Paspatis
Journal: Endoscopy (2019)

Sessile serrated polyps (SSPs) are recognized as a major contributor to the epidemiologic burden of colorectal cancer, although the optimal technique for their removal remains uncertain. We aimed to prospectively evaluate the efficacy and safety of cold endoscopic mucosal resection (c-EMR) for SSPs sized 8 – 20 mm.
Abstract 221: A Non-invasive Technique for Fast Assessment of Optimal LVAD Outflow Graft Implant Sites
Authors: Huidan W YU, Anurag Deb, Xi Chen, Rou Chen, Dongfang Wang, I-Wen Wang
Journal: Circulation Research (2017)

We develop a novel noninvasive technique, named InVascular, for fast hemodynamic assessment of optimal LVAD (left ventricle assist device) outflow-graft (OG) implant suites. LVADs has been a proven and effective therapy for patients with severe end-stage heart failure. Due to the improved pump technology and better patient management, minimally invasive LVAD implantation has emerged as a paradigm shift for clinical surgical techniques. Appropriate OG insertion to either ascending aorta (a), descending thoracic aorta (b), or axillary artery (c) (Fig. 1) is critical in an LVAD surgery. We have recently invented a novel technique that integrates advanced computational modeling based on patient’s CT and ECHO images (Fig. 1d), with cutting-edge GPU (Graphic Processing Units) parallel computing technology to noninvasively quantify 4-D (time+space) flow (Fig. 1e) and pressure in the segment. Comparisons of flow and pressure among 3 OG locations (Fig. 1f) can guide an appropriate OG location for an LVAD implantation. Our results from one study case show that the OG location has important effects on flow in the ascending and descending aorta: OG locations (a) and (b) generate similar flow in the ascending aorta whereas in descending aorta OG location (a) results in larger flow than (b), which is consistent with results in public data. Meanwhile, we found that location (c) produces the smallest flow among the 3 locations in both ascending and descending aorta. Invascular can complete such assessment for an optimal OG site within 30 minutes after a patient’s imaging data are available, which is promising for clinical use in future.
Reply:
Authors: Lovkesh Anand, Ashok Choudhary, Shiv K. Sarin
Journal: Hepatology (2019)

Potential conflict of interest: Nothing to report. We thank Dr. Meher et al. for showing interest in our study1 and in APASL ACLF Research Consortium (AARC) publications. The authors have mentioned 24 participating centers in the study on the Predispoition, Injury, Response, Organ failure (PIRO) model for acute kidney injury2 and 17 centers in our study. In fact, AARC currently has 51 participating centers. As per policy, for a given study, only centers with significant contributions in that area are included: hence the differences. Our study included patients fulfilling acute‐on‐chronic liver failure (ACLF) criteria,3 along with International Autoimmune Hepatitis Group score ≥ 10 or simplified autoimmune hepatitis (AIH) score ≥ 6, supported by histopathology. Six patients had viral infection as the precipitating factor for AIH‐ACLF, of which 3 were hepatitis E virus (HEV) related. Anti‐HEV immunoglobulin M and HEV RNA (if serology positive) was done. It is known that autoimmune serological markers could be false positive or negative, as was seen with 49% of patients in our study being seronegative. However, as histopathology was available in 90% of cases, our cohort was distinctive. Thus, we do not think HEV RNA was needed in seronegative cases. Corticosteroids were only given based on histological findings. Acute AIH can present as acute liver failure (ALF) or ACLF.4 Our study focused on ACLF, as per the Asian Pacific Association for the Study of the Liver definition, which is quite different from ALF; it included patients with underlying chronic liver disease with or without cirrhosis, supported by fibrosis in varying degrees found in all biopsies, convincingly proving diagnosis of acute flare of chronic AIH. Transjugular liver biopsy is helpful in diagnosing AIH‐ACLF, determining etiology, and differentiating from ALF. We agree that the presence of sepsis and hepatorenal syndrome in Group B could influence survival. We compared Group B patients with or without sepsis at baseline (n = 27 in each). No difference in 90‐day survival was seen between groups. Moreover, patients receiving steroids had better 90‐day survival as compared with patients in Group B not receiving corticosteroids, with or without baseline sepsis. We reiterate the need to identify AIH‐ACLF as a distinct entity, for early diagnosis and timely intervention. We disagree with Meher et al. that improving outcome in AIH‐ACLF with corticosteroids is inappropriate. Transplantation is not feasible for all patients with AIH‐ACLF. A selected cohort of patients with AIH‐ACLF, with a Model for End‐Stage Liver Disease score <27, absence of hepatic encephalopathy, and <F3 fibrosis should be offered steroids under close monitoring.
Traitement par NOTES des Fistules digestives post chirurgie bariatrique par drain de KEHR
Authors: M Queralto, A Liagre, P Cabarrot, J Castellano, A Ledit, J Lévy, J Philip, I Roque, N Sigur, Y Anduze, G Juglard
Journal: Endoscopy (2019)

L'avènement des drains Double Queue de Cochon a facilité la gestion des complications de la chirurgie bariatrique à type d'abcès/fistules. Ces prothèses font référence en cas de fistule dont l'orifice est de l'ordre du centimètre, au-delà, il existe un risque de migration prothétique.
Abstract 102: Cardiac Sodium/Glucose Cotransporter 1, a Novel Cardiac Glucose Transporter, Is Cardioprotective in Ischemia-Reperfusion Injury
Authors: Mohun Ramratnam, Sanjay Banerjee, William Witham, Ravi Sharma, Ravi Ramani, Kenneth R McGaffin, Ferhaan Ahmad
Journal: Circulation Research (2012)

Background: The expression of cardiac sodium/glucose cotransporter 1 (SGLT1) is up-regulated in ischemic heart disease. However, the regulation and the biological role of SGLT1 activity in cardiomyocytes are unclear. Hypothesis: We hypothesize that SGLT1 inhibition during ischemia-reperfusion (IR) will lead to worsening cardiac function and recovery. In addition we hypothesize that SGLT1 expression is upregulated by increased AMPK activity in ischemia. Methods: Transgenic mice with cardiac-specific RNAi knockdown of SGLT1 (TG SGLT1-KD ) were subjected to ex vivo IR (n &gt; 3/group) using a Langendorff hanging heart preparation with 15 min of no-flow ischemia and 20 min of reperfusion while undergoing hemodynamic monitoring. FVB strain wild-type 8-12 week-old male mice (n &gt; 3/group) were administered either the SGLT1 inhibitor phlorizin (400 mg/kg IP) or vehicle and subjected to in vivo ischemia for 30 min by ligation of the left anterior descending (LAD) coronary artery. Hearts were harvested 48 hours later. In vitro studies were conducted in HL-1 cardiomyocytes subjected to 1 h of simulated ischemia with 1 mM NaCN. HL-1 cells were also treated with 1 mM AICAR, an AMPK activator, for 16 hours and SGLT1 expression was measured. Results: In ex vivo IR studies, there was an impairment in the early recovery of double product in the TG SGLT1-KD mice compared to control mice (37% vs 92% at 1 min into reperfusion, P &lt; 0.05). In in vivo IR studies, phlorizin led to a marked increase in oxidative stress documented by cardiac malondialdehyde (MDA) (control 1.00±0.00; IR 1.55±0.35; IR + phlorizin 16.15±0.40, P &lt;0.001),an increase in apoptosis documented by TUNEL staining, and hemodynamic impairment: +dP/dt (mmHg/sec), control 11445±504, IR 9811±2613, IR + phlorizin 5139±481, P &lt;0.05; -dP/dt (mmHg/sec), control -10625±589, IR -6770±1142, IR + phlorizin -4153±474, P &lt;0.05. In HL-1 cardiomyocytes, there was a 6.7-fold increase in SGLT1 expression after simulated ischemia, and a 2.0-fold increase after AICAR exposure. Conclusion: SGLT1 expression increases when cardiomyocytes are subjected to ischemia, an effect that may be mediated by AMPK. Inhibition of SGLT1 leads to impaired myocardial recovery from ischemia.
IMPLEMENTATION OF ENDOSCOPIC SUBMUCOSAL DISSECTION (ESD) IN EUROPE – SURVEY AFTER ESD EXPERT TRAINING WORKSHOPS 2009 – 2018
Authors: T Oyama, N Yahagi, F Berr, T Kiesslich, T Ponchon, T Toyonaga, T Uraoka, A Ziachehabi, F Schachinger, H Seifert, G Kaehler, A Wagner, H Messmann, J Hochberger, SV Kantsevoy, A Mitrakov
Journal: Endoscopy (2019)

To obtain information on implementation of ESD in particpating centres of ten experimental ESD Training Workshops in Salzburg [Dig Endosc 2011;23:282 – 89].
2 appels téléphoniques permettent t'ils de garantir une meilleur préparation colique? à propos de 138 cas
Authors: I Jemni, L Safer, R Baklouti, M Ben Abdelwahed, M Zakhama, A Guediche, W Bouhlel, W Ben Mansour, HL Mohamed, BC Nabil
Journal: Endoscopy (2019)

Les difficultés du patient liées à la réalisation du régime sans fibre et à la purge, sont souvent à l'origine d'une préparation colique de mauvaise qualité. Celle-ci entraine une diminution du taux de détection des adénomes, et parfois la nécessité d'une nouvelle coloscopie.
Anti HER-2 therapies and left ventricular dysfunction: A prospective study
Authors: A.J. Daniele, V.E. Gregorietti
Journal: Annals of Oncology (2019)

Background: The Anti Her 2 drugs (AH2D): Trastuzumab (T) and Pertuzumab (P), are very important tool in the treatment of HER2 + Breast Cancer. (BC), who presented left ventricular dysfunction (LVD) in the follow-up. We analysed prospectively a group of p. who presented a LVD after the therapy with an AH2D. We proposed that the early treatment with Beta-Blockers (BB) (Carvedilol), angiotensin-converting enzyme inhibitor (IECA) (Enalapril) or Angiotensin Receptor Blockers (ARBs) (Valsartan), Aldosterone Antagonist (AA) (eplerenone); could to help for an early recovery of left ventricular ejection fraction (LVEF) and to allow the reintroduction of the AH2D without a new risk of LVD. Methods: We analysed 593 consecutive p. with HER2 + BC who received T. alone or with P. from January 2017 to August 2018 with Anthracyclines (A) before or not. Basal LVEF evaluation was made by ultrasonography (US) before to start the oncological treatment. 40 p. developed LV dysfunction with the AH2D. All of the 40 p. started treatment with BB, IECA or ARBs, abd AA at the moment of the diagnosis of HF and kept going it after the recovery of LVEF. The reintroduction of the AH2D was when the patients recovered their LVEF. They were followed-up with LVEF by US at 30 days, 60 days and 3 months. We used the SPSS for the statistical analysis. Results: 40 p. aged 53 +/- 7, 100% female. Risk Factors: Arterial Hypertension 8 p., Diabetes 4 p, Dyslipemia 5 p., Cigarettes 7 p. Previous oncological therapies: A. - Ciclophosphamide 20 p., Paclitaxel 20 p. Median of the basal LVEF was 60 % and at the moment of de diagnosis of HF was 41% New York Heart Association (NYHA) class I 15 %, II 60% and III 25%.All of the p. left the AH2D. HF treatment: Carvedilol 39 p., Enalapril 30 patients, Valsartan 9 p. and Eplerenone 40 p. In the follow-up 80% of p. presented the recovery of LVEF at 30 days and 95% at 60 days. When the p. recovered the LVEF we restarted the AH2D. In the follow-up at 3 months none p. had a new LVD and NYHA class I 30%, II 25% and asymptomatic 45%. Conclusions: While the LVD related with AH2D is a real problem that threat the treatment of patients with Breast Cancer, a timely diagnosis and a treatment with therapies for HF to allow the LVEF recovery and to keep going with the specific oncological therapy. Legal entity responsible for the study: Andrés J. Daniele. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.